Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients

In a large, multicenter, contemporary, 8-year, cohort study, one third of allogeneic-hematopoietic cell transplant (HCT) recipients with Pseudomonas aeruginosa (PSA) infection developed a recurrent infection within 3 months. Antibiotic treatment duration of ≥14 days was the only significantly associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Olearo, Flaminia, Kronig, Ilona, Masouridi-Levrat, Stavroula, Chalandon, Yves, Khanna, Nina, Passweg, Jakob, Medinger, Michael, Mueller, Nicolas J, Schanz, Urs, Van Delden, Christian, Neofytos, Dionysios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368374/
https://www.ncbi.nlm.nih.gov/pubmed/32704511
http://dx.doi.org/10.1093/ofid/ofaa246
_version_ 1783560594557763584
author Olearo, Flaminia
Kronig, Ilona
Masouridi-Levrat, Stavroula
Chalandon, Yves
Khanna, Nina
Passweg, Jakob
Medinger, Michael
Mueller, Nicolas J
Schanz, Urs
Van Delden, Christian
Neofytos, Dionysios
author_facet Olearo, Flaminia
Kronig, Ilona
Masouridi-Levrat, Stavroula
Chalandon, Yves
Khanna, Nina
Passweg, Jakob
Medinger, Michael
Mueller, Nicolas J
Schanz, Urs
Van Delden, Christian
Neofytos, Dionysios
author_sort Olearo, Flaminia
collection PubMed
description In a large, multicenter, contemporary, 8-year, cohort study, one third of allogeneic-hematopoietic cell transplant (HCT) recipients with Pseudomonas aeruginosa (PSA) infection developed a recurrent infection within 3 months. Antibiotic treatment duration of ≥14 days was the only significantly associated variable with reduced recurrence rates of PSA infections in allogeneic-HCT recipients.
format Online
Article
Text
id pubmed-7368374
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-73683742020-07-22 Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients Olearo, Flaminia Kronig, Ilona Masouridi-Levrat, Stavroula Chalandon, Yves Khanna, Nina Passweg, Jakob Medinger, Michael Mueller, Nicolas J Schanz, Urs Van Delden, Christian Neofytos, Dionysios Open Forum Infect Dis Brief Report In a large, multicenter, contemporary, 8-year, cohort study, one third of allogeneic-hematopoietic cell transplant (HCT) recipients with Pseudomonas aeruginosa (PSA) infection developed a recurrent infection within 3 months. Antibiotic treatment duration of ≥14 days was the only significantly associated variable with reduced recurrence rates of PSA infections in allogeneic-HCT recipients. Oxford University Press 2020-06-23 /pmc/articles/PMC7368374/ /pubmed/32704511 http://dx.doi.org/10.1093/ofid/ofaa246 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Olearo, Flaminia
Kronig, Ilona
Masouridi-Levrat, Stavroula
Chalandon, Yves
Khanna, Nina
Passweg, Jakob
Medinger, Michael
Mueller, Nicolas J
Schanz, Urs
Van Delden, Christian
Neofytos, Dionysios
Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
title Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
title_full Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
title_fullStr Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
title_full_unstemmed Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
title_short Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
title_sort optimal treatment duration of pseudomonas aeruginosa infections in allogeneic hematopoietic cell transplant recipients
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368374/
https://www.ncbi.nlm.nih.gov/pubmed/32704511
http://dx.doi.org/10.1093/ofid/ofaa246
work_keys_str_mv AT olearoflaminia optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT kronigilona optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT masouridilevratstavroula optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT chalandonyves optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT khannanina optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT passwegjakob optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT medingermichael optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT muellernicolasj optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT schanzurs optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT vandeldenchristian optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients
AT neofytosdionysios optimaltreatmentdurationofpseudomonasaeruginosainfectionsinallogeneichematopoieticcelltransplantrecipients

Ejemplares similares